Abstract: In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.

Abstract: In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.

Abstract: The invention, in one characterization, may be said to be directed to a radiopharmaceutical system. In some embodiments, the system may include a radioisotope elution component and a radio-frequency identification (RFID) tag coupled to the radioisotope elution component. Other embodiments may include a radiation shielded enclosure having an interior, an exterior, and a radio-frequency identification (RFID) communication transmission passage extending between the interior and the exterior.

Abstract: The present invention is directed to processes for the synthesis of morphinans. In particular, a process for cyclizing a ?,?-bicyclic ketone compound to form a nordihydrothebainone product using the Grewe cyclization reaction is improved by forming a reaction mixture comprising a ?,?-bicyclic ketone compound, a cyclizing acid and a water scavenging cyclization additive. In one embodiment, the Grewe transformation occurs in the presence of an acid anhydride as the cyclization additive. Further, the present invention is directed to processes for converting ?,?-bicyclic ketone compounds (e.g., by-products of the Grewe cyclization reaction) to ?,?-bicyclic ketone compounds, wherein the ?,?-bicyclic ketone compounds may be recovered to further undergo Grewe cyclization and form the nordihydrothebainone product.

Abstract: Novel opiate intermediate compositions and methods of synthesis that include changing the substitution pattern on the aromatic ring of the pre-Grewe intermediate are provided. The intermediates are morphinane derivatives of formula (10), wherein X is a F or Cl and R is selected from the group consisting of an H, alkyl, aryl, acyl, formyl, COR?, CONHR?, COOR, Bn(benzyl), alkyl(methyl), and sulfonamide SO2CH2COPh.

Abstract: The present invention provides a solid support for Fmoc-solid phase synthesis of peptides. In particular, the solid supports of the invention may be utilized to produce peptide acids.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patient who is then diagnosed or treated using the effector molecule.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.

Abstract: A method of pressure regulation and a ventilator are provided. The ventilator includes a positive relative pressure gas supply, a negative relative pressure gas supply, and a diverter valve. The diverter valve includes a positive pressure port connected to the positive relative pressure gas supply, a negative pressure port connected to the negative relative pressure gas supply, and a gas supply port communicating with a gas delivery device. The ventilator preferably further includes a feedback sensor that detects a gas supply difference between a gas supply and a predetermined gas supply and generates a feedback signal that is substantially related to the gas supply difference. The ventilator preferably further includes a diverter valve actuator communicating with the diverter valve and operating the diverter valve to communicate the positive relative pressure gas supply and the negative relative pressure gas supply to the gas supply port of the diverter valve based upon the feedback signal.

Abstract: Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid.

Abstract: Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid.

Abstract: Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid.

Abstract: The present disclosure generally relates to catalytic methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydrocodone, hydromorphone, or a derivative thereof, by means of an isomerization of codeine, morphine, or a derivative thereof, respectively, using a ruthenium catalyst.

Abstract: The present invention provides processes for the preparation of saturated 6-keto, 3-alkoxy morphinans from unsaturated 6-hydroxy, 3-hydroxy morphinans, In particular, the invention provides processes that utilize catalytic isomerization and alkylation reactions for the preparation of saturated 6-keto, 3-alkoxy morphinans.

Abstract: The present invention provides processes for the preparation of saturated ketone morphinan compounds by catalytic isomerization. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an allyl-transition metal catalyst.

Abstract: The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal.

Abstract: A syringe (10?) for use with a powered injector (20) to inject a fluid into a patient that includes a length of material (1550) adapted to transmit or propagate electromagnetic energy therethrough. The length of material (1550) includes a plurality of indicators (60a-60c) positioned along the length of material. The indicators (60a-60c) are adapted to interact with at least a portion of the energy being propagated through the length of material (1550) of the syringe (10?) in a manner that is detectable. An indicator block (1500) may be disposed over at least a portion of the plurality of indicators (60a-60c). The presence (or absence) of an indicator block (1500) provides or corresponds to information about the syringe (10?) configuration. The indicator(s) (60a-60c) in combination with the indicator blocks (1500) may, for example, provide information about syringe (10?) configuration by the number and/or position thereof.

Abstract: The invention relates to the handling of radioactive material. For instance, a radiation shield of the invention may include a body having a cavity therein for receiving radioactive material. An opening to the cavity may be defined in the body. A base may be releasably attachable to the body (generally toward the opening) to at least partially enclose the radioactive material in the cavity. In the case that the radiation shield includes a plurality of interchangeable bases, one of the bases may have at least one of a shorter length and a lighter weight than another of the bases. The base(s) may be designed to enclose more than one size and/or shape of container in the cavity. The base(s) may include a hand grip to facilitate manual gripping of the radiation shield. The base(s) may include a guard to reduce exposure to radiation from manual handling of the radiation shield.

Abstract: Embodiments of the present invention include systems and methods that relate to a sensor with memory. Specifically, one embodiment includes a sensor comprising a light emitting element configured to emit light, a light detecting element configured to detect the light, and a memory storing at least one patient-specific parameter, the memory providing access to an oximeter monitor to read the at least one patient-specific parameter.

Abstract: There is disclosed a novel sustained release granular resin-pharmaceutical composition comprising an ion exchange resin complexed with a pharmaceutical material wherein said complex is embedded into and on the surface of a diffusion barrier material. There is also disclosed a novel process for preparing the granulated complex wherein an aqueous granulating vehicle is employed to form the complex and the granulated product, thereby avoiding the use of coatings and large amounts of organic solvents in the process.